Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology

Brain

Volumn 132, Issue 7, 2009, Pages 1795-1809

  Simunovic, Filip ^a   Yi, Ming ^b   Wang, Yulei ^c   Macey, Laurel ^a   Brown, Lauren T ^a   Krichevsky, Anna M ^d   Andersen, Susan L ^a   Stephens, Robert M ^b   Benes, Francine M ^a   Sonntag, Kai C ^a  

^a MCLEAN HOSPITAL   (United States)

^b SAIC FREDERICK INC   (United States)

^c APPLIED BIOSYSTEMS   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Dopamine; Laser microdissection; Microarray; Parkinson's disease; Pathogenesis

Indexed keywords

ALPHA SYNUCLEIN; DJ 1 PROTEIN; DOPAMINE; GROWTH FACTOR; ION CHANNEL; LEUCINE RICH REPEAT KINASE 2; NEUROTRANSMITTER; NEUROTRANSMITTER RECEPTOR; PARKIN; PROTEIN BCL 2;

AGED; AMINO ACID SEQUENCE; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOSKELETON; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOPAMINERGIC NERVE CELL; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IDIOPATHIC DISEASE; LASER MICRODISSECTION; MALE; MULTIGENE FAMILY; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DEGRADATION; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; UNINDEXED SEQUENCE;

AGED; AGED, 80 AND OVER; APOPTOSIS; CELL SURVIVAL; CYTOSKELETON; DOPAMINE; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; ION CHANNELS; MALE; MICRODISSECTION; MITOCHONDRIA; NERVE TISSUE PROTEINS; NEURONS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PARKINSON DISEASE; PHENOTYPE; RECEPTORS, NEUROTRANSMITTER; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA; SYNAPSES; UBIQUITIN-PROTEIN LIGASES;

EID: 67650070391     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awn323     Document Type: Article

References (61)

1. Benabid AL. What the future holds for deep brain stimulation. Expert Rev Med Devices 2007; 4: 895-903.
2. Benes FM, Lim B, Matzilevich D, Walsh JP, Subburaju S, Minns M. Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars. Proc Natl Acad Sci USA 2007; 104: 10164-9.
3. Boka G, Anglade P, Wallach D, Javoy-Agid F, Agid Y, Hirsch EC. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994; 172: 151-4.
4. Bredesen DE, Rao RV, Mehlen P. Cell death in the nervous system. Nature 2006; 443: 796-802.
5. Brunger AT. Structure and function of SNARE and SNARE-interacting proteins. Q Rev Biophys 2005; 38: 1-47.
6. Burke R. The concept and mechanisms of programmed cell death. In: Factor SA, Weiner WJ, editors. Parkinson's disease: diagnosis and clinical management. New York: Demos Medical Publishing, Inc.; 2007. p. 1-16.
7. Burke RE. Programmed cell death and new discoveries in the genetics of parkinsonism. J Neurochem 2008; 104: 875-90.
8. Cantuti-Castelvetri I, Keller-McGandy C, Bouzou B, Asteris G, Clark TW, Frosch MP, et al. Effects of gender on nigral gene expression and parkinson disease. Neurobiol Dis 2007; 26: 606-14.
9. Cookson MR. The biochemistry of Parkinson's disease. Annu Rev Biochem 2005; 74: 29-52.
10. de Carvalho Aguiar P, Sweadner KJ, Penniston JT, Zaremba J, Liu L, Caton M, et al. Mutations in the Na+/K+ -ATPase alpha3 gene ATP1A3 are associated with rapid-onset dystonia parkinsonism. Neuron 2004; 43: 169-75.
11. Doniger SW, Salomonis N, Dahlquist KD, Vranizan K, Lawlor SC, Conklin BR. MAPPFinder: using Gene Ontology and GenMAPP to create a global gene-expression profile from microarray data. Genome Biol 2003; 4: R7.
12. Duke DC, Moran LB, Kalaitzakis ME, Deprez M, Dexter DT, Pearce RK, et al. Transcriptome analysis reveals link between proteasomal and mito- chondrial pathways in Parkinson's disease. Neurogenetics 2006; 7:139-48.
13. Ferrer I, Blanco R, Cutillas B, Ambrosio S. Fas and Fas-L expression in Huntington's disease and Parkinson's disease. Neuropathol Appl Neurobiol 2000; 26: 424-33.
14. Goldsteins G, Keksa-Goldsteine V, Ahtoniemi T, Jaronen M, Arens E, Akerman K, et al. Deleterious role of superoxide dismutase in the mitochondrial intermembrane space. J Biol Chem 2008; 283:8446-52.
15. Gomez C, Bandez MJ, Navarro A. Pesticides and impairment of mito- chondrial function in relation with the parkinsonian syndrome. Front Biosci 2007; 12: 1079-93.
16. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/ cellular matrix and vesicle trafficking genes. J Neural Transm 2004; 111: 1543-73.
17. Grundemann J, Schlaudraff F, Haeckel O, Liss B. Elevated alpha-synu- clein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res 2008; 36: e38.
18. Hartmann A, Mouatt-Prigent A, Faucheux BA, Agid Y, Hirsch EC. FADD: A link between TNF family receptors and caspases in Parkinson's disease. Neurology 2002; 58: 308-10.
19. Hartmann A, Troadec JD, Hunot S, Kikly K, Faucheux BA, Mouatt- Prigent A, et al. Caspase-8 is an effector in apoptotic death of dopa- minergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001; 21: 2247-55.
20. Hauser MA, Li YJ, Xu H, Noureddine MA, Shao YS, Gullans SR, et al. Expression profiling of substantia nigra in Parkinson disease, progressive supranuclear palsy, and frontotemporal dementia with parkinson- ism. Arch Neurol 2005; 62: 917-21.
21. Kobayashi T, Ikeda K. G protein-activated inwardly rectifying potassium channels as potential therapeutic targets. Curr Pharm Des 2006; 12:4513-23.
22. Lee KH, Kim MY, Kim DH, Lee YS. Syntaxin 1A and receptor for activated C kinase interact with the N-terminal region of human dopa- mine transporter. Neurochem Res 2004; 29: 1405-9.
23. Li J, Smyth P, Cahill S, Denning K, Flavin R, Aherne S, et al. Improved RNA quality and TaqMan Pre-amplification method (PreAmp) to enhance expression analysis from formalin fixed paraffin embedded (FFPE) materials. BMC Biotechnol 2008; 8: 10.
24. Liss B, Haeckel O, Wildmann J, Miki T, Seino S, Roeper J. K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons. Nat Neurosci 2005; 8: 1742-51.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-8.
26. Lu L, Neff F, Dun Z, Hemmer B, Oertel WH, Schlegel J, et al. Gene expression profiles derived from single cells in human postmortem brain. Brain Res Brain Res Protoc 2004; 13: 18-25.
27. Lu L, Neff F, Fischer DA, Henze C, Hirsch EC, Oertel WH, et al. Regional vulnerability of mesencephalic dopaminergic neurons prone to degenerate in Parkinson's disease: a post-mortem study in human control subjects. Neurobiol Dis 2006; 23: 409-21.
28. Lundvig D, Lindersson E, Jensen PH. Pathogenic effects of alpha-synu- clein aggregation. Brain Res Mol Brain Res 2005; 134: 3-17.
29. Luzzi V, Mahadevappa M, Raja R, Warrington JA, Watson MA. Accurate and reproducible gene expression profiles from laser capture microdissection, transcript amplification, and high density oligonucleotide microarray analysis. J Mol Diagn 2003; 5: 9-14.
30. Maguire-Zeiss KA, Federoff HJ. Convergent pathobiologic model of Parkinson's disease. Ann NY Acad Sci 2003; 991: 152-66.
31. Martin LJ, Liu Z, Chen K, Price AC, Pan Y, Swaby JA, et al. Motor neuron degeneration in amyotrophic lateral sclerosis mutant superox- ide dismutase-1 transgenic mice: mechanisms of mitochondriopathy and cell death. J Comp Neurol 2007; 500: 20-46.
32. Matsubayashi H, Inoue A, Amano T, Seki T, Nakata Y, Sasa M, et al. Involvement of alpha7- and alpha4beta2-type postsynaptic nicotinic acetylcholine receptors in nicotine-induced excitation of dopaminer- gic neurons in the substantia nigra: a patch clamp and single-cell PCR study using acutely dissociated nigral neurons. Brain Res Mol Brain Res 2004; 129: 1-7.
33. Michel PP, Alvarez-Fischer D, Guerreiro S, Hild A, Hartmann A, Hirsch EC. Role of activity-dependent mechanisms in the control of dopaminergic neuron survival. J Neurochem 2007; 101: 289-97.
34. Miller RM, Callahan LM, Casaceli C, Chen L, Kiser GL, Chui B, et al. Dysregulation of gene expression in the 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-lesioned mouse substantia nigra. J Neurosci 2004; 24: 7445-54.
35. Miller RM, Federoff HJ. Altered gene expression profiles reveal similarities and differences between Parkinson disease and model systems. Neuroscientist 2005; 11: 539-49.
36. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ. Robust dysregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol Dis 2006; 21:305-13.
37. Mogi M, Harada M, Kondo T, Mizuno Y, Narabayashi H, Riederer P, et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett 1996; 220: 195-8.
38. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiol- ogy of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87.
39. Mootha VK, Lepage P, Miller K, Bunkenborg J, Reich M, Hjerrild M, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 2003; 100:605-10.
40. Moran LB, Croisier E, Duke DC, Kalaitzakis ME, Roncaroli F, Deprez M, et al. Analysis of alpha-synuclein, dopamine and parkin pathways in neuropathologically confirmed parkinsonian nigra. Acta Neuropathol 2007; 113: 253-63.
41. Moran LB, Duke DC, Deprez M, Dexter DT, Pearce RK, Graeber MB. Whole genome expression profiling of the medial and lateral substantia nigra in Parkinson's disease. Neurogenetics 2006; 7: 1-11.
42. Moran LB, Graeber MB. Towards a pathway definition of Parkinson's disease: a complex disorder with links to cancer, diabetes and inflammation. Neurogenetics 2008; 9: 1-13.
43. Olanow CW. The pathogenesis of cell death in Parkinson's disease- 2007. Mov Disord 2007; 22 (Suppl 17): S335-42.
44. Olanow CW, McNaught KS. Ubiquitin-proteasome system and Parkinson's disease. Mov Disord 2006; 21: 1806-23.
45. Quik M, Bordia T, O'Leary K. Nicotinic receptors as CNS targets for Parkinson's disease. Biochem Pharmacol 2007; 74: 1224-34.
46. Raza H, Robin MA, Fang JK, Avadhani NG. Multiple isoforms of mito- chondrial glutathione S-transferases and their differential induction under oxidative stress. Biochem J 2002; 366: 45-55.
47. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol 2007; 8: 519-29.
48. Schapira AH. Future directions in the treatment of Parkinson's disease. Mov Disord 2007; 22 (Suppl 17): S385-91.
49. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc Natl Acad Sci USA 2007; 104: 955-60.
50. Schiesling C, Kieper N, Seidel K, Kruger R. Review: familial Parkinson's disease-genetics, clinical phenotype and neuropathology in relation to the common sporadic form of the disease. Neuropathol Appl Neurobiol 2008; 34: 255-71.
51. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 2008; 3: 1101-8.
52. Scorrano L. Multiple functions of mitochondria-shaping proteins. Novartis Found Symp 2007; 287: 47-55; discussion 55-9.
53. Singh S, Dikshit M. Apoptotic neuronal death in Parkinson's disease:involvement of nitric oxide. Brain Res Rev 2007; 54: 233-50.
54. Stirling PC, Srayko M, Takhar KS, Pozniakovsky A, Hyman AA, Leroux MR. Functional interaction between phosducin-like protein 2 and cytosolic chaperonin is essential for cytoskeletal protein function and cell cycle progression. Mol Biol Cell 2007; 18: 2336-45.
55. Surmeier DJ. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007; 6: 933-8.
56. Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol 2003; 53 (Suppl 3): S61-70; discussion S70-2.
57. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007; 16 (Spec No. 2): R183-94.
58. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-21.
59. Ungewickell EJ, Hinrichsen L. Endocytosis: clathrin-mediated membrane budding. Curr Opin Cell Biol 2007; 19: 417-25.
60. Whitton PS. Inflammation as a causative factor in the aetiology of Parkinson's disease. Br J Pharmacol 2007; 150: 963-76.
61. Yi M, Horton JD, Cohen JC, Hobbs HH, Stephens RM. WholePathwayScope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinform 2006; 7: 30. Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism, and signaling pathways, and suggests novel disease mechanisms. Am J Med Genet B Neuropsychiatr Genet 2005; 137: 5-16.